Jenburkt Pharmaceuticals Ltd Stock Analysis

BSE: 524731 | NSE: | Pharmaceuticals & Drugs | Small Cap

BSE Share Price 09-Jun-2023 15:35
662.50 -16.20 (-2.39%)

DeciZen - Make an Informed Decision on Jenburkt Pharma

Overall Rating
M-Cap below 500cr. High Risk from low Liquidity

1. Quality

2. Valuation

Somewhat overvalued

3. Price Trend

Jenburkt Pharma Price Chart

P/E Ratio ( SA) :
Market Cap :
299.5 Cr.
52-wk low :
52-wk high :
Bole Toh?

1. Is Jenburkt Pharmaceuticals Ltd a good quality company?

Past 10 year's financial track record analysis by Moneyworks4me indicates that Jenburkt Pharmaceuticals Ltd is a good quality company.

2. Is Jenburkt Pharmaceuticals Ltd undervalued or overvalued?

The key valuation ratios of Jenburkt Pharmaceuticals Ltd's currently when compared to its past seem to suggest it is in the Somewhat overvalued zone.

3. Is Jenburkt Pharmaceuticals Ltd a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Jenburkt Pharmaceuticals Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.

10 Year X-Ray of Jenburkt Pharma:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Jenburkt Pharmaceuticals Ltd has performed well in majority of the past ten years indicating its past ten year financial track record is very good

Value Creation

Value Creation Index Colour Code Guide

ROCE % 27.8%28.9%28.5%25.5%25.8%28.2%27.5%17.8%18%19.8%-
Value Creation Index

Growth Parameters

Growth Parameters Colour Code Guide

Sales 69.376.285.293.6103115123119109124137
YoY Gr. Rt. %-9.9%11.8%9.8%10.4%11%7%-3.1%-8.1%13.4%-
Adj EPS 13.115.720.722.928.936.943.231.835.647.955.8
YoY Gr. Rt. %-20.5%31.7%10.5%26.3%27.7%17%-26.3%11.8%34.5%-
BVPS (₹) 48.758.771.986.4117.1133.5168.8174.3214.6255.8277.3
Adj Net Profit
Cash Flow from Ops. 4.511.48.77.81016.2131519.59.4-
Debt/CF from Ops.


CAGR Colour Code Guide

9 Years 5 Years 3 Years 1 Years
Sales 6.7%3.7%0.4%13.4%
Adj EPS 15.5%10.6%3.5%34.5%
BVPS 20.216.914.919.2
Share Price 24.5% -2.3% 21.8% 23.3%

Key Financial Parameters

Performance Ratio Colour Code Guide

Return on Equity % 29.329.331.728.928.429.328.618.618.320.420.9
Op. Profit Mgn % 14.615.117.917.619.120.720.416.618.22222.2
Net Profit Mgn % 8.89.611.311.41314.816.212.31517.718
Debt to Equity
Working Cap Days 107867371656984101129177207
Cash Conv. Cycle 44383438373956716246167

Recent Performance Summary

Return on Equity has increased versus last 3 years average to 20.90%

Sales growth is good in last 4 quarters at 11.17%

Sales growth has been subdued in last 3 years 0.36%

Net Profit has been subdued in last 3 years 3.49%

Latest Financials - Jenburkt Pharmaceuticals Ltd.

Standalone Consolidated
TTM EPS (₹) 55.8 -
TTM Sales (₹ Cr.) 137 -
BVPS (₹.) 277.3 -
Reserves (₹ Cr.) 118 -
P/BV 2.45 -
PE 12.17 -
From the Market
52 Week Low / High (₹) 452.10 / 800.00
All Time Low / High (₹) 1.80 / 880.00
Market Cap (₹ Cr.) 300
Equity (₹ Cr.) 4.4
Face Value (₹) 10
Industry PE 38.1

Management X-Ray of Jenburkt Pharma :

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *
* Pledged shares as % of Promoter's holding (%)

Event Update

Login/Register to view analysis.

Analyst's Notes

Key Ratios of Jenburkt Pharma

Adj EPS (Rs.)
Sales (Cr.)
ROE (%)
ROCE (%)


Jenburkt Pharmaceuticals Ltd FAQs

Company share prices are keep on changing according to the market conditions. The closing price of Jenburkt Pharma on 09-Jun-2023 15:35 is : 662.5.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 09-Jun-2023 15:35 the market cap of Jenburkt Pharma stood at ₹ 299.5.
The latest PE ratio of Jenburkt Pharma as of 09-Jun-2023 15:35 is 12.17.
The latest PB ratio of Jenburkt Pharma as of 09-Jun-2023 15:35 is 2.45
The 52-week high of Jenburkt Pharma is ₹ 800.0 and the 52-week low is ₹ 452.1.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue / sales of Jenburkt Pharma is ₹ 136.8 ( Cr.) .

About Jenburkt Pharmaceuticals Ltd

Jenburkt Pharmaceuticals Ltd, a venture to diversify into the healthcare and pharmaceutical industry, was formed in 1985 by the Bhuta family; late Hemendra N. Bhuta was the promoter of the company while the Bhuta Group was founded by Nandlal Mulji Bhuta

Jenburkt is engaged in manufacturing and marketing of speciality and high quality pharmaceutical formulations and healthcare products. Jenburkt is a public limited company, with its stock listed on the Bombay Stock Exchange. Jenburkt's headquarters are ocated in Mumbai, from where it’s entire operations

The company has a state-of-the-art manufacturing plants at Sihor-Gujarat,in India. The plant is modern and well equipped with spacious operational areas having adequate capacities for manufacturing world-class pharmaceutical and healthcare products.

The plant is approved as per WHO guidelines for compliances with current GMPrequirements, apart from approvals from various countries.

Jenburkt, has 25 superstockists located in different corners of India, it has approximately 1000 stockists, who buy from Superstockist and sell to chemists. Jenburkt also caters to large government, semi-government institutions, missionary hospitals, public sector enterprises, etc.

Product range of the company includes: 

Consumer Division:

  • Nocal Tablets
  • Nocal Sachet   
  • Nocal Granular 

Pharmaceutical Division: 

  • Anti-Arthritic
  • Antibiotics 
  • Anti-Diabetic 
  • Nutraceuticals 
  • Anti-Inflammory Analgesics 
  • Gastro Intenstinal 
  • Dermatologicals
  • Aphrodisiac 
  • Anti-Osteoporotic
  • Anti-Cough, Cold & Allergy
  • Anti-Ulcerants


2010 - The Company was bestowed with "National Award for Excellence in Cost Management-2009" as the "FIRST" awardees under the category of the "Private Manufacturing-(small)" by the Institute of Cost and Works Accountants of India (ICWAI), at New Delhi.
2011 - The Company was bestowed with "National Award for Excellence in Cost Management-2010" as the "FIRST"awardee under the category of the "Private Manufacturing-(small)" by the Institute of Cost and Works Accountants of India (ICWAI).
The Company has been awarded an NSIC-CRISIL rating of "NSIC-CRISIL SE-1A" on June 30, 2011. The rating indicates ""Highest performance capability and High financial strength".

Read More Read Less
You have 2 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login | Register Now